Pemvidutide vs BI 456906
Head-to-head comparison of Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Pemvidutide | BI 456906 |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | N/A | N/A |
| Half-Life | Approximately 1 week | Approximately 1 week |
| Amino Acids | N/A | N/A |
| Typical Dose | Trial-dependent; once-weekly SC titration | Trial-dependent; weekly SC dosing |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 18 | 10 |
| Research Status | Clinical | Clinical |
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.